Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A

 Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A

Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A

Shots:

  • The P-IIIb/IV PROPEL study involves assessing of Adynovate in prophylaxis targeting two different FVIII trough levels (1–3% REF/ 8–12% ELE) in prior treated patients with severe hemophilia A
  • The P-IIIb/IV PROPEL study resulted in enhancing a patient’s PK profile by targeting ELE vs REF, patients with zero bleed (62% vs % vs 42%), reduction in ABR (1.6 vs 3.6), reduction in spontaneous joint ABR (0.5 vs 2.0) respectively
  • Adynovate (Antihemophilic Factor (Recombinant), PEGylated) is a factor replacement therapy and has received FDA’s approval followed by approval in Japan, Canada and is approved as Adynovi in Europe for the treatment & prophylaxis of bleeding in patients with hemophilia A aged ≥ 12yrs.

Click here to read full press release/ article | Ref: Takeda | Image: Financial Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post